The record amount spent by the Pharmaceutical Care Management Association comes as the Trump administration works to finalize a proposal that would ultimately ban the rebates drugmakers pay to the managers. The proposal could overhaul how drug prices are set and how drugs are paid.
The management association strictly opposes a ban on rebates.
PBMs have also faced increased criticism from lawmakers and the public recently about their role in the drug industry. Last month, top executives from five large benefit managers faced tough questions from Congress during a high-stakes hearing on drug prices.
More articles on pharmacy:
Torrent Pharmaceuticals recalls 104 more lots of blood pressure drug
Civica Rx opens Utah headquarters
GlaxoSmithKline to lay off more than 240 workers in US, UK